Prevention of acute myocardial infarction induced heart failure by intracoronary infusion of mesenchymal stem cells: phase 3 randomised clinical trial (PREVENT-TAHA8).

ABSTRACT:

Objective

To assess the effect of intracoronary infusion of mesenchymal stem cells on the development of post-myocardial infarction heart failure.

Design

Phase 3 randomised clinical trial.

Setting

Three tertiary hospitals in Shiraz, Iran.

Participants

420 patients with a first ST segment elevation acute myocardial infarction and left ventricular ejection fraction <40% were enrolled and randomised in a 1:2 ratio to receive intervention or standard care.

Intervention

Intracoronary infusion of allogenic Wharton's jelly derived mesenchymal stem cells within 3-7 days of acute myocardial infarction in addition to standard care.

Main outcome measures

The primary endpoint was incidence of heart failure. Secondary endpoints included readmission to hospital

SUBMITTER: Attar A 

PROVIDER: S-EPMC12570275 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature